

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
14 August 2003 (14.08.2003)

PCT

(10) International Publication Number
WO 03/066589 A1(51) International Patent Classification⁷: **C07D 211/58**,
401/04, 405/12, A61K 31/451, 31/4525, 31/5377, 31/497,
A61P 25/22, 25/24

(21) International Application Number: PCT/GB03/00499

(22) International Filing Date: 5 February 2003 (05.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0203021.1 8 February 2002 (08.02.2002) GB
0203019.5 8 February 2002 (08.02.2002) GB(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **ALVARO, Giuseppe** [IT/TT]; GlaxoSmithKline SpA, Via Alessandro Fleming2, I-37135 Verona (IT). **PAIO, Alfredo** [IT/TT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37135 Verona (IT). **PONTIROLI, Alessandro** [IT/TT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37135 Verona (IT). **SPADA, Simone** [IT/TT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37135 Verona (IT). **TRANQUILLINI, Maria, Elvira** [IT/TT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37135 Verona (IT).(74) Agent: **THOMPSON, Clive, Beresford**; CN925.1, 980 Great West Road, Brentford, Middlesex TW7 9GS (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: PIPERIDYLCARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TACHYKINIM-MEDIATED DISEASES



(57) Abstract: The present invention relates to piperidine derivatives of formula (I) wherein R represents halogen or C₁₋₄alkyl; R₁ represents hydrogen or C₁₋₄ alkyl; R₂ represents hydrogen, C₁₋₄ alkyl or R₂ together with R₃ represents C₃₋₇ cycloalkyl; R₃ represents hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl or C₃₋₆ alkenyl; or R₁ and R₃ together with nitrogen and carbon atom to which they are attached respectively represent a 5 to 6 membered heterocyclic group; R₄ represents trifluoromethyl, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethoxy or halogen; R is hydrogen and R is NR₇R₈ or R₅ is NR₈R₉ and R₆ is hydrogen; R₇ represents hydrogen or C₁₋₄ alkyl or R₇ and R₈ together with nitrogen to which they are attached are a saturated 5 to 7 membered heterocyclic group containing oxygen; R₈ represents hydrogen, phenyl, C₃₋₇ cycloalkyl, (CH₂)_pC(O)NR₁₀R₁₁, a saturated 5 to 7 membered heterocyclic group containing 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen and optionally substituted by C₁₋₄ alkyl, S(O)₂C₁₋₄ alkyl or C(O) C₁₋₄ alkyl, a 5 membered heteroaryl group containing 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen and optionally substituted by C₁₋₄ alkyl S(O)₂C₁₋₄alkyl or C(O) C₁₋₄ alkyl or R₈ represents a 6 membered heteroaryl group containing 1 to 3 nitrogen atoms and optionally substituted by C₁₋₄alkyl, S(O)₂C₁₋₄ alkyl or C(O) C₁₋₄alkyl; or R₈ is a C₁₋₆ alkyl group optionally substituted by one or two groups selected from fluorine, phenyl(optionally substituted by C₁₋₄ alkyl, C(O) C₁₋₄ alkyl or halogen), =O, C₃₋₇cycloalkyl, hydroxy, amino, dimethylamino, aminocarbonyl, C₁₋₄alkoxy or trifluoromethyl; R₉ is hydrogen, C₁₋₄ alkyl or R₉ and R₈ together with nitrogen to which they are attached are a 5 to 7 membered heterocyclic group optionally containing another heteroatom selected from oxygen, sulphur and nitrogen and optionally substituted by one or two groups selected from C₁₋₄ alkyl, =O, S(O)₂C₁₋₄ alkyl, C(O) C₃₋₇cycloalkyl or C(O) C₁₋₄ alkyl; R₁₀ and R₁₁ are independently hydrogen or C₁₋₄ alkyl group; X represents a nitrogen atom and Y is CH or X represents CH and Y is nitrogen; m is zero or an integer from 1 to 3; n is an integer from 1 to 3; p is zero, 1 or 2; and pharmaceutically acceptable salts and solvates thereof; the process for their preparation and their use in the treatment of conditions mediated by tachykinins.